- Conditions
- Hemophagocytic Lymphohistiocytosis
- Interventions
- ATG, rabbit, Etoposide, Methotrexate, hydrocortisone, Dexamethasone
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • San Francisco, California • Stanford, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 447
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Vitamin C Deficiency, Smoking, Surgery, Surgery--Complications, Wound, Wound Complication, Wound Infection, Wound Dehiscence, Wound of Skin, Mandible Fracture, Mandible Open Fracture, Mandible Closed Fracture, Mandibular Fractures, Ascorbic Acid Deficiency, Oxidative Stress, Inflammation
- Interventions
- Vitamin C, Placebo
- Dietary Supplement · Other
- Lead sponsor
- Hennepin Healthcare Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Obesity, Morbid, Surgery, Bariatric Surgery Candidate
- Interventions
- Neurontin, Dilaudid Injectable Product, Marcaine Injectable Product, Oxycodone Hydrochloride, Hycet 7.5Mg-325Mg/15Ml Solution, Zofran Injection, Scopolamine patch, Ativan, Flexeril Oral Product, Tylenol Suspension
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 35 Years to 65 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Warm Autoimmune Hemolytic Anemia
- Interventions
- ALXN1830, Placebo
- Biological · Other
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Whittier, California
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Cytarabine, Daunorubicin, Electrocardiography, Pemigatinib
- Procedure · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Dallas, Texas
- Conditions
- Vascular Access Complications
- Interventions
- AccuCath IV Catheter System, Conventional IV Catheter System
- Device
- Lead sponsor
- C. R. Bard
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hemorrhagic Shock
- Interventions
- Premarin IV, Placebo
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 2
- States / cities
- Dallas, Texas
- Conditions
- Untreated Adult Acute Myeloid Leukemia
- Interventions
- midostaurin, azacitidine, bone marrow aspiration, mutation analysis, Pharmacokinetic study
- Drug · Other
- Lead sponsor
- Brenda Cooper, MD
- Other
- Eligibility
- Not listed
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Morgantown, West Virginia
- Conditions
- Chronic Lung Disease
- Interventions
- Lyophilized Palivizumab, Liquid Palivizumab
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- Up to 24 Months
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Hoover, Alabama • Tuscaloosa, Alabama + 45 more
- Conditions
- Pancreatic Cancers, Pancreatic Diseases
- Interventions
- Not listed
- Lead sponsor
- Do Hyun Park
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 263 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Cleveland, Ohio
- Conditions
- Multiple Sclerosis (MS)
- Interventions
- Ocrelizumab, rHuPH20
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 18
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Alexandria, Louisiana + 15 more
- Conditions
- Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive
- Interventions
- Blood drawing, Bronchoalveolar lavage during indicated bronchoscopy
- Procedure
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic, Pancreas Cancer, Pancreatic Cancer
- Interventions
- Talabostat Mesylate
- Drug
- Lead sponsor
- BioXcel Therapeutics Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Hypothermia; Anesthesia, Hypothermia, Newborn, Hypothermia, Sequela
- Interventions
- Pre op upper body forced air warming (32˚C), Pre op lower body forced air warming (32˚C), Pre op fluids (45˚C), Intra op upper body forced air warming (32˚C), Intra op fluids at room temperature, Intra op upper body forced air warming at (32˚C), Intra op upper body forced air warming at (42˚C), Intra op lower body forced air warming at (32˚C), Intra op lower body forced air warming at (42˚C), Intra op fluid (42˚C)
- Device
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Interventions
- gemcitabine hydrochloride, floxuridine, proteomic profiling, matrix-assisted laser desorption/ionization time of flight mass spectrometry, liquid chromatography, yttrium Y 90 anti-CEA monoclonal antibody cT84.66, laboratory biomarker analysis, mass spectrometry, pharmacological study
- Drug · Genetic · Other + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2018
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Primary Immunodeficiency Diseases (PID)
- Interventions
- SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety), SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety), IV treatment with IGSC, 10%
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 11
- States / cities
- Cypress, California • Irvine, California • Los Angeles, California + 8 more
- Conditions
- Huntington's Disease
- Interventions
- Not listed
- Lead sponsor
- University College, London
- Other
- Eligibility
- 11 Years to 75 Years
- Enrollment
- 2,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2017
- U.S. locations
- 6
- States / cities
- Englewood, Colorado • Washington D.C., District of Columbia • Baltimore, Maryland + 3 more
- Conditions
- Systemic Sclerosis-Associated PAH
- Interventions
- Rituximab, Placebo, CMRI, prednisone, methylprednisolone, diphenhydramine, acetaminophen
- Biological · Other · Diagnostic Test + 1 more
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 17
- States / cities
- Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more
- Conditions
- Diabetes Complications, Diabetes Mellitus, Diabetic Neuropathies
- Interventions
- IGIV-C, 0.9% Sodium Chloride
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Venetoclax, Cytarabine, Idarubicin, Intrathecal Triple Therapy, Azacitidine
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Chapel Hill, North Carolina • Memphis, Tennessee
- Conditions
- Lymphoma, Large B-Cell, Diffuse
- Interventions
- Durvalumab, Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone, Lenalidomide
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 7
- States / cities
- Gilbert, Arizona • Fort Wayne, Indiana • Rochester, Minnesota + 4 more
- Conditions
- Adenotonsillectomy, Analgesia, Surgery
- Interventions
- Dexamethasone, Ibuprofen, Acetaminophen, Placebo
- Drug
- Lead sponsor
- David Chi, MD
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Sewickley, Pennsylvania
- Conditions
- Healthy Subjects
- Interventions
- VNRX-5133 + cefepime
- Drug
- Lead sponsor
- Venatorx Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Hartford, Connecticut
- Conditions
- Premature Rupture of Membrane, Unfavorable Cervix
- Interventions
- Intracervical balloon catheter, Oxytocin
- Device · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Chicago, Illinois